Sally Hed recently became the sole owner of Bloomington-based ImmunoChemistry Technologies, a 10-employee company that makes biotechnology tools that, since 1994, have helped researchers at places like the National Institutes of Health and the World Health Organization find remedies for a host of maladies and diseases.
"We sell 'red and green stuff' that makes their tests better," said Hed, referring to a line of substances that help researchers determine the effect of various treatments on human cells. "It really makes a difference.
"Using our 'reagent' to monitor the effectiveness of treatment [enables cancer] patients to try a different drug right away, rather than waiting longer and suffering through painful side effects," Hed said. "It's one more way new diagnostic technology can personalize medicine specific for each patient."
After years of struggle and near bankruptcy that were averted only when ImmunoChemistry earned its first major patent and sold it in 2014 plus royalties, the company is cash-flowing on about $3 million in revenue.
Hed, 46, who holds degrees in genetics and cell biology from the University of Minnesota, joined the fledgling company in 1996 from a job as a lab analyst at a larger company. She wanted to become a shareholder in a small growth company.
It's been a sometimes volatile run. Including several tough years over the last decade that meant no salary at times for the owners and cost Hed her sailboat, luxury apartment and a boyfriend she'd rather forget.
She and the company averted financial collapse with a several-year sacrifice plan that eventually stabilized Immuno.
And now the future looks pretty good.